Final AnswerBased on the Phase 3 data, Sofdra (15% sofpironium...

Final Answer

Based on the Phase 3 data, Sofdra (15% sofpironium bromide gel) and EccLock (5% sofpironium bromide gel) demonstrate highly similar efficacy for primary axillary hyperhidrosis, with comparable rates of symptom relief (82.8–89.9% vs. 83.0–85.7% at 6 weeks for patient-reported outcomes) and sweat reduction (54.3–68.7% vs. 53.9–58.2% for ≥50% reduction with symptom improvement). Safety profiles are also similar, with mild application site reactions and anticholinergic effects, though Sofdra has higher rates of anticholinergic AEs (e.g., dry mouth: 11.6–17.2% vs. ≤1.1%), likely due to its higher concentration.

Therapeutic equivalence ?